Pan-Malaria Transmission-Blocking Vaccine AnAPN1 - Trial NCT05905432
Access comprehensive clinical trial information for NCT05905432 through Pure Global AI's free database. This Phase 1 trial is sponsored by Centre de Recherche Médicale de Lambaréné and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centre de Recherche Médicale de Lambaréné
Timeline & Enrollment
Phase 1
Jul 25, 2023
Dec 31, 2023
Primary Outcome
Adverse events related to the vaccination.
Summary
Malaria is still responsible for more than 627,000 deaths each year, predominantly among
 children under 5 years old. Current reductions in deaths have stagnated, and additional
 setbacks for malaria control programs due to the Coronavirus Disease 2019 (COVID-19) pandemic
 are expected. To achieve malaria elimination and eradication a leverage concerted approaches
 to reduce clinical disease and prevent new infections is a must. The existing malaria
 controls tools including the a recombinant protein-based malaria vaccine (RTS,S ,(trade name
 MosquirixMosquirix )), a malaria vaccine currently undergoing implementation studies and
 endorsed by the World Health Organization on October 7, 2021, can reduce disease burden for
 patients but cannot ultimately support malaria elimination and eradication since their effect
 on malaria transmission is at most partial. Consequently, complementary interventions, such
 as transmission-blocking vaccines (TBVs) may prove to be a cost-effective intervention that
 can reduce on-going residual transmission and the cascade of new infections.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05905432
Non-Device Trial